Peptide outcomes across different populations
The desired direction of change depends on the problem. A useful comparison begins with the purpose of the experiment.
Preserving weight and reducing weight
In the ferret cisplatin experiment, ipamorelin reduced weight loss without preventing vomiting. In adults in SURMOUNT-1, tirzepatide produced greater weight loss than placebo. The animals were experiencing chemotherapy-associated weight loss; the human trial enrolled people with obesity, or overweight with a weight-related complication, without diabetes. Direction alone tells very little until the setting is restored.
I enjoy the collision because it exposes how much a slogan such as metabolic benefit leaves unspecified. Neither study compares the two compounds, and neither supplies a reason to substitute one for the other.
The ipamorelin medians
Ipamorelin’s bowel-resection trial makes a different comparison problem visible. The median time to a first tolerated meal was 25.3 hours with ipamorelin and 32.6 hours with placebo. With p=0.15, the primary endpoint was missed. The bars below show the reported medians; the test result limits the conclusion that can follow them.
A summary that rests its whole argument on the shorter bar earns my objection. It is possible to report the directional difference accurately and still exaggerate what the study established.
Skin, hair and desire
The 45-man hair trial tested a combination containing GHK. Giving GHK-Cu all the credit erases the other ingredient and the form of peptide used. Small topical trials and cell experiments ask different questions from an untested systemic-use claim.
Bremelanotide’s Phase 3 trials measured desire and desire-related distress in premenopausal women with HSDD. Its long-term extension recorded nausea at 40.4%. A questionnaire improvement and a burden of treatment can both be real, while their balance remains personal.
Across this collection, the most useful next experiment changes with the compound: a convincing human outcome for ipamorelin, clearer formulation-specific clinical results for GHK-Cu, a better account of meaningful individual benefit for PT-141, and longer-term benefit and burden for tirzepatide. I see no sensible common score that would preserve those differences.